Upgrade to SI Premium - Free Trial

Amedisys (AMED) Tops Q3 EPS by 2c, Miss on Revenues

November 7, 2017 5:02 PM

Amedisys (NASDAQ: AMED) reported Q3 EPS of $0.56, $0.02 better than the analyst estimate of $0.54. Revenue for the quarter came in at $380.2 million versus the consensus estimate of $385.5 million.

Three Month Periods Ended September 30, 2017 and 2016

Adjusted Quarterly Results*

For earnings history and earnings-related data on Amedisys (AMED) click here.

Categories

Earnings Guidance

Next Articles